FZD10

Summary

FZD10 (frizzled class receptor 10, HGNC:4039) is a protein-coding gene on chromosome 12q24.33, encoding Frizzled-10 (Q9ULW2). Receptor for Wnt proteins.

This gene is a member of the frizzled gene family. Members of this family encode 7-transmembrane domain proteins that are receptors for the Wingless type MMTV integration site family of signaling proteins. Most frizzled receptors are coupled to the beta-catenin canonical signaling pathway. Using array analysis, expression of this intronless gene is significantly up-regulated in two cases of primary colon cancer.

Source: NCBI Gene 11211 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 86 total
• Druggable target: yes
• MANE Select transcript: NM_007197

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4039
Approved symbol	FZD10
Name	frizzled class receptor 10
Location	12q24.33
Locus type	gene with protein product
Status	Approved
Aliases	CD350
Ensembl gene	ENSG00000111432
Ensembl biotype	protein_coding
OMIM	606147
Entrez	11211

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000229030, ENST00000539839

RefSeq mRNA: 1 — MANE Select: NM_007197 NM_007197

CCDS: CCDS9267

Canonical transcript exons

ENST00000229030 — 1 exons

Exon	Start	End
ENSE00002290283	130162464	130165740

Expression profiles

Bgee: expression breadth ubiquitous, 191 present calls, max score 93.47.

FANTOM5 (CAGE): breadth broad, TPM avg 2.3268 / max 337.7078, expressed in 352 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
128719	2.2224	343
128720	0.0697	29
128721	0.0230	4
128718	0.0118	3

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
gingival epithelium	UBERON:0001949	93.47	gold quality
gingiva	UBERON:0001828	91.72	gold quality
cartilage tissue	UBERON:0002418	88.80	gold quality
squamous epithelium	UBERON:0006914	86.85	gold quality
cervix squamous epithelium	UBERON:0006922	86.57	gold quality
epithelium of esophagus	UBERON:0001976	84.95	gold quality
esophagus squamous epithelium	UBERON:0006920	84.65	gold quality
pharyngeal mucosa	UBERON:0000355	83.35	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.55	gold quality
cervix epithelium	UBERON:0004801	82.17	gold quality
synovial joint	UBERON:0002217	81.62	gold quality
lower esophagus mucosa	UBERON:0035834	81.47	gold quality
esophagus mucosa	UBERON:0002469	79.79	gold quality
penis	UBERON:0000989	78.51	gold quality
oral cavity	UBERON:0000167	78.01	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	76.95	silver quality
skin of hip	UBERON:0001554	76.45	gold quality
skin of abdomen	UBERON:0001416	76.24	gold quality
zone of skin	UBERON:0000014	75.74	gold quality
oviduct epithelium	UBERON:0004804	75.47	gold quality
tongue squamous epithelium	UBERON:0006919	74.92	silver quality
skin of leg	UBERON:0001511	74.89	gold quality
mammalian vulva	UBERON:0000997	74.62	gold quality
upper leg skin	UBERON:0004262	73.08	gold quality
vagina	UBERON:0000996	71.84	gold quality
tibialis anterior	UBERON:0001385	71.62	silver quality
layer of synovial tissue	UBERON:0007616	71.14	gold quality
uterine cervix	UBERON:0000002	70.36	gold quality
endothelial cell	CL:0000115	70.30	silver quality
placenta	UBERON:0001987	70.30	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.69

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

72 targeting FZD10, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-545-3P	99.95	70.74	2783
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-4493	99.90	66.48	977
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-3941	99.86	70.54	2735
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-221-5P	99.86	65.45	1052
HSA-MIR-8073	99.86	65.21	1118
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-3133	99.81	70.92	3506
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-6885-3P	99.75	70.36	3187

Literature-anchored findings (GeneRIF, showing 10)

• there was a strong inverse correlation between nuclear immunostaining scores for beta-catenin expression and expression patterns of FZD10 (PMID:19134005)
• FZD10 transactivation causes the activation of the Dvl-Rac1-JNK pathway and is associated with the development/progression of synovial sarcomas (PMID:19137009)
• the selective expression of FZD10 in brain vascular endothelial cells points at a potential role of FZD10-Galpha13 signalling in central nervous system angiogenesis. (PMID:28126591)
• The tumor associated antigen hFZD10 produced as a fusion protein with mTEM7 could be used to enrich scFv antibodies from a yeast display library. (PMID:29500915)
• N(6)-methylation of adenosine of FZD10 mRNA contributes to PARP inhibitor resistance in the ovarian cancer cells. (PMID:30967398)
• SEPT9_v2, frequently silenced by promoter hypermethylation, exerts anti-tumor functions through inactivation of Wnt/beta-catenin signaling pathway via miR92b-3p/FZD10 in nasopharyngeal carcinoma cells. (PMID:32138771)
• A Possible Role of FZD10 Delivering Exosomes Derived from Colon Cancers Cell Lines in Inducing Activation of Epithelial-Mesenchymal Transition in Normal Colon Epithelial Cell Line. (PMID:32933173)
• Targeting fatty acid synthase sensitizes human nasopharyngeal carcinoma cells to radiation via downregulating frizzled class receptor 10. (PMID:32944403)
• [Exosomal FZD10 derived from non-small cell lung cancer cells promotes angiogenesis of human umbilical venous endothelial cells in vitro]. (PMID:36210708)
• N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells’ Properties and Lenvatinib Resistance Through WNT/beta-Catenin and Hippo Signaling Pathways. (PMID:36764493)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	fzd10	ENSDARG00000068213
mus_musculus	Fzd10	ENSMUSG00000081683
rattus_norvegicus	Fzd10	ENSRNOG00000022784
drosophila_melanogaster	fz3	FBGN0027343
caenorhabditis_elegans		WBGENE00022242

Paralogs (15): FZD3 (ENSG00000104290), SFRP1 (ENSG00000104332), SFRP4 (ENSG00000106483), SFRP5 (ENSG00000120057), SMO (ENSG00000128602), SFRP2 (ENSG00000145423), FZD7 (ENSG00000155760), FZD1 (ENSG00000157240), FRZB (ENSG00000162998), FZD5 (ENSG00000163251), FZD6 (ENSG00000164930), FZD4 (ENSG00000174804), FZD8 (ENSG00000177283), FZD2 (ENSG00000180340), FZD9 (ENSG00000188763)

Protein

Protein identifiers

Frizzled-10 — Q9ULW2 (reviewed: Q9ULW2)

Alternative names: FzE7

All UniProt accessions (2): Q9ULW2, F5H450

UniProt curated annotations — full annotation on UniProt →

Function. Receptor for Wnt proteins. Functions in the canonical Wnt/beta-catenin signaling pathway. The canonical Wnt/beta-catenin signaling pathway leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes. A second signaling pathway involving PKC and calcium fluxes has been seen for some family members, but it is not yet clear if it represents a distinct pathway or if it can be integrated in the canonical pathway, as PKC seems to be required for Wnt-mediated inactivation of GSK-3 kinase. Both pathways seem to involve interactions with G-proteins. May be involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues.

Subunit / interactions. Interacts with WNT7B. Interacts with MYOC.

Subcellular location. Cell membrane.

Tissue specificity. Highest levels in the placenta and fetal kidney, followed by fetal lung and brain. In adult brain, abundantly expressed in the cerebellum, followed by cerebral cortex, medulla and spinal cord; very low levels in total brain, frontal lobe, temporal lobe and putamen. Weak expression detected in adult brain, heart, lung, skeletal muscle, pancreas, spleen and prostate.

Post-translational modifications. Ubiquitinated by ZNRF3, leading to its degradation by the proteasome.

Domain organisation. Lys-Thr-X-X-X-Trp motif interacts with the PDZ domain of Dvl (Disheveled) family members and is involved in the activation of the Wnt/beta-catenin signaling pathway. The FZ domain is involved in binding with Wnt ligands.

Similarity. Belongs to the G-protein coupled receptor Fz/Smo family.

RefSeq proteins (1): NP_009128* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000539	Frizzled/Smoothened_7TM	Domain
IPR015526	Frizzled/SFRP	Family
IPR017981	GPCR_2-like_7TM	Domain
IPR020067	Frizzled_dom	Domain
IPR036790	Frizzled_dom_sf	Homologous_superfamily

Pfam: PF01392, PF01534

UniProt features (40 total): helix 9, topological domain 8, transmembrane region 7, disulfide bond 5, glycosylation site 3, short sequence motif 2, strand 2, signal peptide 1, chain 1, domain 1, region of interest 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
7X8T	X-RAY DIFFRACTION	2.51
7X8Q	X-RAY DIFFRACTION	2.65

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9ULW2-F1	81.10	0.54

Antibody-complex structures (SAbDab): 2 — 7X8Q, 7X8T

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (5): 34–95, 42–88, 79–117, 106–147, 110–134

Glycosylation sites (3): 48, 153, 485

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-373080	Class B/2 (Secretin family receptors)

MSigDB gene sets: 154 (showing top): BENPORATH_ES_WITH_H3K27ME3, GU_PDEF_TARGETS_DN, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GOBP_CELLULAR_RESPONSE_TO_LIPID, JAEGER_METASTASIS_DN, GOBP_NON_CANONICAL_WNT_SIGNALING_PATHWAY, GOBP_POSITIVE_REGULATION_OF_MAPK_CASCADE, GOCC_CELL_SURFACE, GOBP_NEUROGENESIS, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_REGULATION_OF_ACTIN_FILAMENT_BASED_PROCESS, GOBP_CELLULAR_RESPONSE_TO_RETINOIC_ACID, GOBP_CANONICAL_WNT_SIGNALING_PATHWAY, LU_TUMOR_VASCULATURE_UP, KEGG_PATHWAYS_IN_CANCER

GO Biological Process (10): neuron differentiation (GO:0030182), regulation of actin cytoskeleton organization (GO:0032956), non-canonical Wnt signaling pathway (GO:0035567), positive regulation of JNK cascade (GO:0046330), canonical Wnt signaling pathway (GO:0060070), cellular response to retinoic acid (GO:0071300), signal transduction (GO:0007165), cell surface receptor signaling pathway (GO:0007166), G protein-coupled receptor signaling pathway (GO:0007186), Wnt signaling pathway (GO:0016055)

GO Molecular Function (5): G protein-coupled receptor activity (GO:0004930), Wnt-protein binding (GO:0017147), Wnt receptor activity (GO:0042813), transmembrane signaling receptor activity (GO:0004888), protein binding (GO:0005515)

GO Cellular Component (6): obsolete extracellular space (GO:0005615), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), plasma membrane (GO:0005886), cell surface (GO:0009986), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
GPCR ligand binding	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
Wnt signaling pathway	3
signal transduction	2
transmembrane signaling receptor activity	2
cell differentiation	1
generation of neurons	1
actin cytoskeleton organization	1
regulation of actin filament-based process	1
regulation of cytoskeleton organization	1
JNK cascade	1
positive regulation of MAPK cascade	1
regulation of JNK cascade	1
response to retinoic acid	1
cellular response to lipid	1
cellular response to oxygen-containing compound	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
G protein-coupled receptor activity	1
cell surface receptor signaling pathway	1
G protein-coupled receptor signaling pathway	1
protein binding	1
Wnt-protein binding	1
signaling receptor activity	1
binding	1
nuclear lumen	1
intracellular anatomical structure	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

994 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FZD10	WNT7A	O00755	954
FZD10	WNT7B	P56706	879
FZD10	WNT1	P04628	835
FZD10	CTNNB1	P35222	725
FZD10	HILPDA	Q9Y5L2	700
FZD10	WNT2B	Q93097	689
FZD10	LRP5	O75197	680
FZD10	WNT3A	P56704	671
FZD10	WNT2	P09544	658
FZD10	LRP6	O75581	645
FZD10	WNT9B	O14905	629
FZD10	WNT10A	Q9GZT5	629
FZD10	WNT10B	O00744	623
FZD10	FRAT2	O75474	548
FZD10	WNT11	O96014	546

IntAct

90 interactions, top by confidence:

A	B	Type	Score
FZD10	P4HB	psi-mi:“MI:0915”(physical association)	0.560
NOTCH2NLC	FZD10	psi-mi:“MI:0915”(physical association)	0.560
KRTAP10-8	FZD10	psi-mi:“MI:0915”(physical association)	0.560
KRTAP1-1	FZD10	psi-mi:“MI:0915”(physical association)	0.560
CYSRT1	FZD10	psi-mi:“MI:0915”(physical association)	0.560
CCNDBP1	FZD10	psi-mi:“MI:0915”(physical association)	0.560
P4HB	FZD10	psi-mi:“MI:0915”(physical association)	0.560
FZD10	NRP1	psi-mi:“MI:0914”(association)	0.530
LNX2	FZD10	psi-mi:“MI:0407”(direct interaction)	0.440
FZD10	APBA1	psi-mi:“MI:0407”(direct interaction)	0.440
FZD10	PATJ	psi-mi:“MI:0407”(direct interaction)	0.440
FZD10	HTRA1	psi-mi:“MI:0407”(direct interaction)	0.440
FZD10	PDZD2	psi-mi:“MI:0407”(direct interaction)	0.440
FZD10	RADIL	psi-mi:“MI:0407”(direct interaction)	0.440
SYNJ2BP	FZD10	psi-mi:“MI:0407”(direct interaction)	0.440
FZD10	PDZD7	psi-mi:“MI:0407”(direct interaction)	0.440
FZD10	HTRA4	psi-mi:“MI:0407”(direct interaction)	0.440
FZD10	TAMALIN	psi-mi:“MI:0407”(direct interaction)	0.440
FZD10	ARHGEF11	psi-mi:“MI:0407”(direct interaction)	0.440
FZD10	MAGI2	psi-mi:“MI:0407”(direct interaction)	0.440
FZD10	NOS1	psi-mi:“MI:0407”(direct interaction)	0.440
FZD10	LNX1	psi-mi:“MI:0407”(direct interaction)	0.440
FZD10	MAGI3	psi-mi:“MI:0407”(direct interaction)	0.440
ARHGAP21	FZD10	psi-mi:“MI:0407”(direct interaction)	0.440
FZD10	DLG4	psi-mi:“MI:0407”(direct interaction)	0.440
FZD10	SNX27	psi-mi:“MI:0407”(direct interaction)	0.440
MAST2	FZD10	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (99): EVI5 (Affinity Capture-MS), TMED8 (Affinity Capture-MS), GSTCD (Affinity Capture-MS), VPS8 (Affinity Capture-MS), ATRIP (Affinity Capture-MS), EVI5L (Affinity Capture-MS), VEZT (Affinity Capture-MS), RINT1 (Affinity Capture-MS), NCAPD2 (Affinity Capture-MS), XPO7 (Affinity Capture-MS), XPO4 (Affinity Capture-MS), ATP6V0A2 (Affinity Capture-MS), C4orf32 (Affinity Capture-MS), TNPO2 (Affinity Capture-MS), HEATR3 (Affinity Capture-MS)

ESM2 similar proteins: B3DIG4, O00144, O57328, O57329, O70421, O75084, O93274, P18537, P23385, P27115, P27808, P41594, P55013, P58421, P97772, Q08463, Q08464, Q13255, Q13467, Q14332, Q24760, Q498S8, Q5BL72, Q5RH73, Q61090, Q61091, Q6NVG7, Q6P9A2, Q6PA90, Q8AVJ9, Q8BKG4, Q8CHL0, Q8IYK4, Q8K4C8, Q9DEB5, Q9EQD0, Q9H461, Q9I9M5, Q9IA02, Q9IA06

Diamond homologs: A0A0K3AWM6, B3DIG4, G5ECQ2, O00144, O19116, O42579, O57328, O57329, O60353, O70421, O75084, O93274, P18537, P58421, P97299, P97401, Q08463, Q08464, Q13467, Q14332, Q24760, Q498S8, Q5BL72, Q5RCN4, Q5RF67, Q5T4F7, Q61086, Q61088, Q61089, Q61090, Q61091, Q6FHJ7, Q7YRN1, Q80YN4, Q863H1, Q8AVJ9, Q8BKG4, Q8C4U3, Q8CHL0, Q8K4C8

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
WNT7B	up-regulates	FZD10	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 61 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Assembly and cell surface presentation of NMDA receptors	7	43.3×	3e-08
Neurexins and neuroligins	6	28.8×	5e-06
Signaling by Rho GTPases	7	5.8×	2e-03
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	7	5.7×	2e-03

GO biological processes:

GO term	Partners	Fold	FDR
establishment or maintenance of epithelial cell apical/basal polarity	7	70.1×	3e-09
receptor clustering	5	53.8×	5e-06
cell-cell adhesion	5	8.8×	8e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

86 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	85
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

14 predictions. Top by Δscore:

Variant	Effect	Δscore
12:130162652:GCC:G	donor_gain	0.5400
12:130162651:GGCC:G	donor_gain	0.5300
12:130162652:GCCG:G	donor_gain	0.5300
12:130162655:G:GG	donor_gain	0.5300
12:130162654:C:CG	donor_gain	0.4600
12:130164334:C:CA	acceptor_gain	0.4600
12:130162529:G:T	donor_gain	0.3600
12:130164347:AT:A	acceptor_gain	0.3000
12:130162660:T:TA	donor_gain	0.2800
12:130162528:G:GT	donor_gain	0.2500
12:130164334:C:G	acceptor_gain	0.2400
12:130164347:ATG:A	acceptor_gain	0.2400
12:130162972:G:T	acceptor_gain	0.2100
12:130164338:C:CA	acceptor_gain	0.2100

AlphaMissense

3840 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:130163066:T:A	C42S	1.000
12:130163067:G:C	C42S	1.000
12:130163177:T:A	C79S	1.000
12:130163178:G:A	C79Y	1.000
12:130163178:G:C	C79S	1.000
12:130163259:G:A	C106Y	1.000
12:130163291:T:A	C117S	1.000
12:130163291:T:C	C117R	1.000
12:130163292:G:C	C117S	1.000
12:130163324:T:A	W128R	1.000
12:130163324:T:C	W128R	1.000
12:130163326:G:C	W128C	1.000
12:130163326:G:T	W128C	1.000
12:130163381:T:A	C147S	1.000
12:130163382:G:C	C147S	1.000
12:130164017:T:A	W359R	1.000
12:130164017:T:C	W359R	1.000
12:130163042:T:A	C34S	0.999
12:130163043:G:C	C34S	0.999
12:130163066:T:C	C42R	0.999
12:130163067:G:A	C42Y	0.999
12:130163068:C:G	C42W	0.999
12:130163153:T:C	F71L	0.999
12:130163154:T:G	F71C	0.999
12:130163155:C:A	F71L	0.999
12:130163155:C:G	F71L	0.999
12:130163177:T:C	C79R	0.999
12:130163178:G:T	C79F	0.999
12:130163179:C:G	C79W	0.999
12:130163204:T:A	C88S	0.999

dbSNP variants (sampled 300 via entrez): RS1000275742 (12:130164872 GGTTTT>G,GGTTTTGTTTT), RS1000687130 (12:130165276 C>G,T), RS1001075114 (12:130165175 CG>C), RS1001140534 (12:130165135 A>G), RS1002195419 (12:130161006 C>T), RS1002654261 (12:130160813 G>A), RS1002855092 (12:130165074 T>C), RS1003069900 (12:130162835 G>A), RS1003608704 (12:130163146 G>T), RS1003922200 (12:130165960 G>A), RS1004181716 (12:130165605 G>A), RS1004740463 (12:130160592 G>C), RS1005984193 (12:130162983 T>G), RS1006185066 (12:130162809 G>A,T), RS1006342917 (12:130161226 A>G)

Disease associations

OMIM: gene MIM:606147 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST001601_3	Gambling	4.000000e-06
GCST003983_41	Male-pattern baldness	4.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004699	gambling behaviour

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4523492 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Class Frizzled GPCRs

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, decreases expression	7
trichostatin A	increases expression	2
Panobinostat	increases expression, affects cotreatment	2
Benzo(a)pyrene	increases expression, increases methylation	2
Estradiol	affects cotreatment, decreases expression, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
methylmercuric chloride	decreases expression	1
bisphenol A	decreases methylation	1
beta-lapachone	increases expression	1
arsenite	increases methylation	1
tobacco tar	decreases expression	1
mercuric bromide	decreases expression	1
pentabromodiphenyl ether	increases expression	1
deguelin	increases expression	1
entinostat	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
torcetrapib	increases expression	1
quinocetone	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
bisphenol S	decreases methylation	1
Cyclic AMP	affects cotreatment, decreases expression	1
Ethanol	increases expression	1
Ascorbic Acid	affects cotreatment, decreases expression	1
Chelating Agents	affects binding, affects expression	1
Copper	affects binding, affects expression	1
Succimer	decreases expression, affects cotreatment	1
Pesticides	decreases methylation	1
Progesterone	affects cotreatment, decreases expression	1
Silicon Dioxide	decreases expression	1
Smoke	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4376178	Binding	Binding affinity to Frizzled-10 CRD (unknown origin)	Lead Optimization Yields High Affinity Frizzled 7-Targeting Peptides That Modulate Clostridium difficile Toxin B Pathogenicity in Epithelial Cells. — J Med Chem

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_0237	Capan-1	Cancer cell line	Male
CVCL_0A59	Capan1M9	Cancer cell line	Male
CVCL_S022	Capan-1 SimpleCell O-GalNAc	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.